NASDAQ:APRE Aprea Therapeutics (APRE) Stock Price, News & Analysis $0.70 -0.03 (-3.94%) Closing price 03:59 PM EasternExtended Trading$0.72 +0.02 (+3.17%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Aprea Therapeutics Stock (NASDAQ:APRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aprea Therapeutics alerts:Sign Up Key Stats Today's Range$0.69▼$0.7450-Day Range$0.60▼$0.9852-Week Range$0.55▼$1.69Volume862,203 shsAverage Volume908,970 shsMarket Capitalization$8.75 millionP/E RatioN/ADividend YieldN/APrice Target$3.07Consensus RatingHold Company Overview Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on restoring the function of mutated p53, a tumor-suppressor protein that is altered in many cancers and plays an important role in regulating cell growth and programmed cell death. Aprea’s pipeline has included eprenetapopt (APR-246), an investigational therapy designed to reactivate mutant p53, as well as next-generation p53-reactivating compounds such as APR-548. These programs have been investigated for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company’s products remain investigational and are subject to clinical and regulatory development. Founded in 2002, Aprea has conducted research and clinical development activities in the United States and internationally, including through studies involving patients with blood cancers. As a development-stage biotechnology company, its operations and prospects depend primarily on advancing its drug candidates through clinical testing and obtaining regulatory approval.AI Generated. May Contain Errors. Read More Aprea Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreAPRE MarketRank™: Aprea Therapeutics scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAprea Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAprea Therapeutics has a consensus price target of $3.07, representing about 324.7% upside from its current price of $0.72.Amount of Analyst CoverageAprea Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aprea Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aprea Therapeutics are expected to decrease in the coming year, from ($0.34) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aprea Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aprea Therapeutics is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAprea Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aprea Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.10% of the float of Aprea Therapeutics has been sold short.Short Interest Ratio / Days to CoverAprea Therapeutics has a short interest ratio ("days to cover") of 3.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aprea Therapeutics has recently decreased by 6.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAprea Therapeutics does not currently pay a dividend.Dividend GrowthAprea Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News SentimentN/A News SentimentAprea Therapeutics has a news sentiment score of -0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.Search Interest2 people have searched for APRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.49% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.19% of the stock of Aprea Therapeutics is held by institutions.Read more about Aprea Therapeutics' insider trading history. Receive APRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APRE Stock News HeadlinesAprea Therapeutics將於11月公布WEE1抑制劑臨床試驗最新數據September 23, 2026 | hk.investing.comAprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR SymposiumSeptember 22, 2026 | globenewswire.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.October 2 at 1:00 AM | SmartAsset (Ad)Contrasting Alkermes (NASDAQ:ALKS) & Aprea Therapeutics (NASDAQ:APRE)September 22, 2026 | americanbankingnews.comAprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comAprea Expands Patent Portfolio For Precision Oncology ProgramsAugust 28, 2026 | rttnews.comAprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology ProgramsAugust 28, 2026 | globenewswire.comAprea Therapeutics records second consecutive surge, jumping another 22%August 25, 2026 | seekingalpha.comSee More Headlines APRE Stock Analysis - Frequently Asked Questions How have APRE shares performed this year? Aprea Therapeutics' stock was trading at $0.8530 at the beginning of the year. Since then, APRE shares have decreased by 15.4% and is now trading at $0.7220. How were Aprea Therapeutics' earnings last quarter? Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.11. When did Aprea Therapeutics' stock split? Aprea Therapeutics shares reverse split before market open on Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aprea Therapeutics IPO? Aprea Therapeutics (APRE) raised $85 million in an IPO on Thursday, October 3rd 2019. The company issued 5,666,667 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO. How do I buy shares of Aprea Therapeutics? Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aprea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings8/12/2026Today10/02/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 APRE's financial health is in the Green zone, according to TradeSmith. APRE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APRE CIK1781983 Webwww.aprea.com Phone(215) 948-4119FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Aprea Therapeutics$3.07 High Price Target$5.00 Low Price Target$1.20 Potential Upside/Downside+339.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.60 million Net MarginsN/A Pretax Margin-246,140.02% Return on Equity-47.60% Return on Assets-40.97% Debt Debt-to-Equity RatioN/A Current Ratio13.56 Quick Ratio13.56 Sales & Book Value Annual Sales$290 thousand Price / Sales30.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.52 per share Price / Book0.46Miscellaneous Outstanding Shares12,590,000Free Float11,270,000Market Cap$8.79 million OptionableNo Data Beta1.66 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:APRE) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
